Adherence to stage-specific treatment guidelines for patients with colon cancer

Journal of Clinical Oncology

Volumn 30, Issue 9, 2012, Pages 972-979

  Chagpar, Ryaz ^a   Xing, Yan ^a   Chiang, Yi Ju ^a   Feig, Barry W ^a   Chang, George J ^a   You, Y Nancy ^a   Cormier, Janice N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURGERY; COLON ADENOCARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOCIAL STATUS; TREATMENT OUTCOME; ADENOCARCINOMA; CANCER STAGING; COLON TUMOR; FOLLOW UP; MIDDLE AGED; PATHOLOGY; PROGNOSIS; QUALITY CONTROL;

ADENOCARCINOMA; ADULT; AGED; COLONIC NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; QUALITY CONTROL; YOUNG ADULT;

EID: 84860603299     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.6937     Document Type: Article

References (49)

1. Hewitt ME, Simone JV, National Cancer Policy Board: Ensuring Quality Cancer Care. Washington, DC, National Academy Press, 1999
2. Somerfield MR, Einhaus K, Hagerty KL, et al: American Society of Clinical Oncology clinical practice guidelines: Opportunities and challenges. J Clin Oncol 26:4022-4026, 2008
3. Desch CE, McNiff KK, Schneider EC, et al: American Society of Clinical Oncology/National Comprehensive Cancer Network Quality Measures. J Clin Oncol 26:3631-3637, 2008
4. National Quality Forum Measure Details: National Voluntary Consensus Standards for Quality of Cancer Care. http://www.qualityforum.org/Publications/ 2009/05/National-Voluntary-Consensus-Standards-for-Quality-of-Cancer-Care.aspx
5. Blayney DW, McNiff K, Hanauer D, et al: Implementation of the Quality Oncology Practice Initiative at a university comprehensive cancer center. J Clin Oncol 27:3802-3807, 2009
6. Agency for Healthcare Research and Quality: Homepage. http://www.qualityindicators.ahrq.gov/
7. The Joint Commission's Annual Report on Quality and Safety: Improving America's hospitals. http://www.jointcommission.org/assets/1/18/2010-Annual- Report.pdf
8. Stulberg JJ, Delaney CP, Neuhauser DV, et al: Adherence to surgical care improvement project measures and the association with postoperative infections. JAMA 303:2479-2485, 2010
9. Jacobson JO, Neuss MN, McNiff KK, et al: Improvement in oncology practice performance through voluntary participation in the Quality Oncology Practice Initiative. J Clin Oncol 26:1893-1898, 2008
10. Bach PB: Using practice guidelines to assess cancer care quality. J Clin Oncol 23:9041-9043, 2005
11. McGlynn EA, Asch SM, Adams J, et al: The quality of health care delivered to adults in the United States. N Engl J Med 348:2635-2645, 2003 (Pubitemid 36741592)
12. Smith TJ, Hillner BE: Ensuring quality cancer care by the use of clinical practice guidelines and critical pathways. J Clin Oncol 19:2886-2897, 2001 (Pubitemid 32538199)
13. Kahn JM, Scales DC, Au DH, et al: An official American Thoracic Society policy statement: Pay-for-performance in pulmonary, critical care, and sleep medicine. Am J Respir Crit Care Med 181:752-761, 2010
14. Inouye SK, Brown CJ, Tinetti ME: Medicare nonpayment, hospital falls, and unintended consequences. N Engl J Med 360:2390-2393, 2009
15. US Department of Health and Human Services: http://www.cms.gov/home/rsds. asp
16. Fung CH, Lim YW, Mattke S, et al: Systematic review: The evidence that publishing patient care performance data improves quality of care. Ann Intern Med 148:111-123, 2008 (Pubitemid 351651554)
17. Lindenauer PK, Remus D, Roman S, et al: Public reporting and pay for performance in hospital quality improvement. N Engl J Med 356:486-496, 2007 (Pubitemid 46193076)
18. Kahn KL, Adams JL, Weeks JC, et al: Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA 303:1037-1045, 2010
19. Greenberg CC, Lipsitz SR, Neville B, et al: Receipt of appropriate surgical care for Medicare beneficiaries with cancer. Arch Surg 146:1128-1134, 2011
20. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. http://www.nccn.org/professionals/physician-gls/f- guidelines.asp
21. Benson AB 3rd, Schrag D, Somerfield MR, et al: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408-3419, 2004 (Pubitemid 41103700)
22. National Cancer Institute: SEER Cancer Statistics Review 1975-2008. http://seer.cancer.gov/csr/1975-2008/results-merged/sect-06-colon-rectum.pdf
23. Winchester DP, Stewart AK, Phillips JL, et al: The national cancer data base: Past, present, and future. Ann Surg Oncol 17:4-7, 2010
24. Bilimoria KY, Stewart AK, Winchester DP, et al: The National Cancer Data Base: A powerful initiative to improve cancer care in the United States. Ann Surg Oncol 15:683-690, 2008
25. American Joint Committee on Cancer: AJCC Cancer Staging Manual (ed 6). Chicago, IL, Springer, 2002
26. Cress RD, Zaslavsky AM, West DW, et al: Completeness of information on adjuvant therapies for colorectal cancer in population-based cancer registries. Med Care 41:1006-1012, 2003
27. Bastos DA, Ribeiro SC, de Freitas D, et al: Combination therapy in high risk stage II or stage III colon cancer: Current practice and future prospects. Ther Adv Med Oncol 2:261-272, 2010
28. Dotan E, Cohen SJ: Challenges in the management of stage II colon cancer. Semin Oncol 38:511-520, 2011
29. Dai J, Li Z, Rocke D: Hierarchical logistic regression modeling withSASGLIMMIX.http://www.lexjansen.com/wuss/2006/Analytics/ANL-Dai.pdf
30. O'Connell AA, McCoach DB: Applications of hierarchical linear models for evaluations of health interventions: Demystifying the methods and interpretations of multilevel models. Eval Health Prof 27:119-151, 2004 (Pubitemid 38590841)
31. Cohen ME, Dimick JB, Bilimoria KY, et al: Risk adjustment in the American College of Surgeons National Surgical Quality Improvement Program: A comparison of logistic versus hierarchical modeling. J Am Coll Surg 209:687-693, 2009
32. Peng C, Lee K, Ingersoll G: An introduction to logistic regression analysis and reporting. J Educ Res 96:3-14, 2002
33. Quasar Collaborative Group, Gray R, Barnwell J, et al: Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 370:2020-2029, 2007
34. André T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116, 2009
35. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17:1356-1363, 1999
36. Kuebler JP, Wieand HS, O'Connell MJ, et al: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 25:2198-2204, 2007 (Pubitemid 46954643)
37. Gill S, Loprinzi CL, Sargent DJ, et al: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 22:1797-1806, 2004 (Pubitemid 41095169)
38. Wilkinson NW, Yothers G, Lopa S, et al: Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: Pooled analysis of NSABP C-01 through C-05 - A baseline from which to compare modern adjuvant trials. Ann Surg Oncol 17:959-966, 2010
39. Figueredo A, Charette ML, Maroun J, et al: Adjuvant therapy for stage II colon cancer: A systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 22:3395-3407, 2004 (Pubitemid 41103699)
40. Sargent DJ, Goldberg RM, Jacobson SD, et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091-1097, 2001
41. Compton CC: Optimal pathologic staging: Defining stage II disease. Clin Cancer Res 13:6862s-6870s, 2007
42. National Cancer Institute: Phase III randomized study of oxaliplatin, leucovorin calcium, and fluorouracil with versus without bevacizumab in patients with resected stage II colon cancer and at high risk for recurrence based on molecular markers. http://www.cancer.gov/clinicaltrials/ECOG-E5202
43. Guyatt G, Oxman AD, Akl EA, et al: GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383-394, 2011
44. Poonacha TK, Go RS: Level of scientific evidence underlying recommendations arising from the National Comprehensive Cancer Network clinical practice guidelines. J Clin Oncol 29:186-191, 2011
45. Sargent D, Sobrero A, Grothey A, et al: Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 27:872-877, 2009
46. Hu CY, Delclos GL, Chan W, et al: Assessing the initiation and completion of adjuvant chemotherapy in a large nationwide and population-based cohort of elderly patients with stage-III colon cancer. Med Oncol 28:1062-1074, 2011
47. Keating NL, Landrum MB, Klabunde CN, et al: Adjuvant chemotherapy for stage III colon cancer: Do physicians agree about the importance of patient age and comorbidity? J Clin Oncol 26:2532-2537, 2008
48. Centers for Medicare and Medicaid Services: Medicare program; hospital inpatient value-based purchasing program. Final rule. Fed Regist 76: 26490-26547, 2011
49. Balshem H, Helfand M, Schünemann HJ, et al: GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64:401-406, 2011